Abstract：
BACKGROUND: The Coronavirus disease-2019 (COVID-19) pandemic continues, and the death toll continues to surge. This meta-analysis aimed to determine the efficacy of mesenchymal stem cells (MSCs) on mortality in patients with COVID-19.
METHODS: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of COVID-19 with MSCs, compared with placebo or blank, were reviewed. Studies were pooled to risk ratios (RRs), with 95% confidence intervals (CIs).
RESULTS: Seventeen RCTs (enrolling 1019 participants) met the inclusion criteria. MSCs showed significant effect on 28-day mortality (RR 0.76, 95% CI 0.62 to 0.93; P = 0.008). There was no statistically significant difference in 60-day mortality (RR 0.87, 95% CI 0.70 to 1.09; P = 0.22), and 90-day mortality (RR 0.91, 95% CI 0.72 to 1.15; P = 0.44) between the two groups.
CONCLUSIONS: MSCs significantly reduced 28-day mortality in patients with COVID-19. The long-term effect of MSCs on mortality require further study.
METHODS: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of COVID-19 with MSCs, compared with placebo or blank, were reviewed. Studies were pooled to risk ratios (RRs), with 95% confidence intervals (CIs).
RESULTS: Seventeen RCTs (enrolling 1019 participants) met the inclusion criteria. MSCs showed significant effect on 28-day mortality (RR 0.76, 95% CI 0.62 to 0.93; P = 0.008). There was no statistically significant difference in 60-day mortality (RR 0.87, 95% CI 0.70 to 1.09; P = 0.22), and 90-day mortality (RR 0.91, 95% CI 0.72 to 1.15; P = 0.44) between the two groups.
CONCLUSIONS: MSCs significantly reduced 28-day mortality in patients with COVID-19. The long-term effect of MSCs on mortality require further study.
摘要：
背景：2019年冠状病毒病（COVID-19）大流行仍在继续，死亡人数继续激增。这项荟萃分析旨在确定间充质干细胞（MSCs）对COVID-19患者死亡率的影响。
方法：对PubMed进行了系统搜索，Embase,科克伦图书馆,和临床试验,没有语言限制。用MSCs治疗COVID-19的随机对照试验（RCTs），与安慰剂或空白相比，被审查了。研究汇总到风险比(RR)，95%置信区间(CI)。
结果：17项RCT（纳入1019名参与者）符合纳入标准。MSCs对28天死亡率有显著影响(RR0.76,95%CI0.62~0.93;P=0.008)。60天死亡率差异无统计学意义(RR0.87,95%CI0.70~1.09;P=0.22),和90天死亡率（RR0.91，95％CI0.72至1.15；P=0.44）。
结论：MSCs显著降低了COVID-19患者的28天死亡率。MSCs对死亡率的长期影响需要进一步研究。
方法：对PubMed进行了系统搜索，Embase,科克伦图书馆,和临床试验,没有语言限制。用MSCs治疗COVID-19的随机对照试验（RCTs），与安慰剂或空白相比，被审查了。研究汇总到风险比(RR)，95%置信区间(CI)。
结果：17项RCT（纳入1019名参与者）符合纳入标准。MSCs对28天死亡率有显著影响(RR0.76,95%CI0.62~0.93;P=0.008)。60天死亡率差异无统计学意义(RR0.87,95%CI0.70~1.09;P=0.22),和90天死亡率（RR0.91，95％CI0.72至1.15；P=0.44）。
结论：MSCs显著降低了COVID-19患者的28天死亡率。MSCs对死亡率的长期影响需要进一步研究。
